

Correspondence

Jean Bousquet, Institute of Allergology, Charité –
Universitätsmedizin Berlin, Corporate Member of Freie
Universität Berlin and Humboldt-Universität zu Berlin,
Berlin, Germany.

Email: jean.bousquet@orange.fr

ORCID

Bernardo Sousa-Pinto  <https://orcid.org/0000-0002-1277-3401>

Jean Bousquet  <https://orcid.org/0000-0002-4061-4766>

REFERENCES

1. Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of patient-reported outcomes in routine medical care. *Am Soc Clin Oncol Educ Book*. 2018;38:122-134.
2. Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). *Health Serv Insights*. 2013;6:61-68.

3. Bousquet J, Arnavielhe S, Bedbrook A, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. *Clin Transl Allergy*. 2018;8:45.
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014;43(2):343-373.
5. GINA report 2021. <https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf>. Accessed January 30, 2022
6. Bakdash JZ, Marusich LR. Repeated measures correlation. *Front Psychol*. 2017;8:456.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

DOI: 10.1111/all.15249

Research impact analysis of international funding agencies in the realm of allergy and immunology

To the Editor,

A longitudinal approach should be employed for research and development (R&D) on allergic and immunological diseases across all life stages. To strategically use limited public funds in promoting such R&D, their characteristics of long-term research support and societal implementation should be considered.¹ However, outcomes of the funding research evaluation have focused on conventional, shortsighted indicators. To determine the kind of indicators needed for the funding strategy, we compared the research impact of funding agencies (FAs) in the UK, US, and Japan, utilizing indices related to research substantiality² and analyzing index words/abstracts connected with the national strategy for allergy and immunology.³

We used AMEDfind—an open database of top-down R&D projects funded by AMED—and selected 53 awards for a Practical Research Project for Allergic Diseases and Immunology (AMED-PPAI) (Figure S1). 1053 papers with verified PubMed IDs were included. As the controls, we selected the Hypersensitivity,

Autoimmune, and Immune-mediated Diseases Study Section (NIH-HAI), an immunology-focused project in the Americas, and Human Immunology Unit (MRC-HIU), that in Europe, extracting 373 US papers and 118 UK papers, published in 2015–2019, respectively (see Appendix S1 for all methods).

The Field-Weighted Citation Impact (FWCI)—evaluating research paper quality—was highest for MRC-HIU following NIH-HAI and AMED-PPAI (Table 1, Figure 1A). Although the international co-authorship rate was lowest in the AMED-PPAI, the annual trend showed a gradual increase (Figure 1B, Table 1). The number of top 10% most cited papers²/value, evaluating funding efficiency, was highest for MRC-HIU (Table 1).

To characterize these outputs, we performed natural language analyses of the top 50 FWCI papers from three FAs and top 100 papers on this topic during 2015–2019 (Figure 1C–E).⁴ Although all FAs produced mainly basic allergy/immunology study papers (e.g., clusters 0, 1, 2, and 9 in Figure 1D), AMED-PPAI produced relatively

Abbreviations: AMED-PPAI, Practical Research Project for Allergic Diseases and Immunology of the Japan Agency for Medical Research and Development; EU, European Union; FA, Funding agency; FWCI, Field-Weighted Citation Impact; MeSH, Medical Subject Headings; METI, Ministry of Economy, Trade and Industry of Japan; MEXT, Ministry of Education, Culture, Sports, Science and Technology of Japan; MHLW, Ministry of Health, Labour and Welfare of Japan; MRC-HIU, Human Immunology Unit of the Medical Research Council; NIH-HAI, Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section of the National Institutes of Health; R&D, Research and development; UK, United Kingdom; UMAP, Uniform Manifold Approximation and Projection; US, United States of America.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

TABLE 1 Comparison of publications and societal impact of research funded by international funding agencies

	AMED-PPAI	MRC-HIU	NIH-HAI	UK comparator	Mann-Whitney-Wilcoxon distribution <i>p</i> values
FWCI	1.92	3.45	2.48		
No. of publications (2015–2019)	1053	118	373		
Value of awards (million USD, 2015–2019)	23.6	8.86	35.3		
No. of publications/value	37.3	9.35	7.09		
International co-authorship percentage	1.36	4.17	1.60		
No. of top 10% most cited papers	10.2	5.3	3.9		
No. of top 10% most cited papers/value	0.432	0.598	0.110		
No. of awards	53			1376	N/A
Value of awards (million USD, 2013–2018)	20.9			521	N/A
Mean value/award	0.393			0.379	.71
Mean funding period (years)	2.90			3.00	.071
No. of intellectual properties/value	0.00473			0.00155	.039(*)
No. of publications/value	0.509			0.118	2.43E-13(***)
Ratio of CC-BY papers	0.350			0.486	N/A
Value of further funding/value	1.58			2.97	.0019(**)
No. of engagement activities/value	0.0909			0.100	.71

Abbreviations: AMED-PPAI, Practical Research Project for Allergic Diseases and Immunology of the AMED; FWCI, Field-Weighted Citation Impact; MRC-HIU, Human Immunology Unit of the MRC; N/A, not applicable; NIH-HAI, Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section of the NIH; No, number; USD, United States Dollar.

* $p < .05$, ** $p < .01$, *** $p < .001$.

more clinically relevant outputs (clusters 3 and 8). Further, we analyzed MeSH headings for relevance to national unique Strategic Outlook toward 2030 formulated by the Ministry of Health, Labour and Welfare of Japan (Figure 1F, Table S1).³ While most projects were pathogenic studies, AMED-PPAI funded research published more papers on precision medicine and host-extrinsic factor relations (Action I-2, I-3). The Action II and III groups were not strongly represented.

To assess societal impact, we utilized ResearchFish—a widely used database of the FAs in Europe⁵—to randomly select 1376 UK-funding awards and their reports, trend-matched for the AMED-PPAI (UK comparator) (Table S2). The number of intellectual properties and publications per value was higher for AMED-PPAI, while the open access rate and new funding amount obtained were higher in the UK comparator (Table 1). Despite the similar number of engagement activities, their outreach targets differed (AMED toward public and media; the UK towards students, patients, and industry; Figure 1G).

The purpose of this study is not to compete for superiority among countries or FAs but to expand the possibilities for multi-dimensional interpretation of trends and characteristics of funded outcomes using multiple indicators rather than uniform one. Due to the limitation of open databases, we focused on three countries for the funding impact analysis, whereas scholarly output in this realm is also increasing in other countries and jurisdictions, including the EU (Figure S2). China's growth is particularly remarkable, and additional analysis is desirable with public funding status.⁶ Furthermore, the

indices used have different trends among countries, and their balance should be carefully considered to reflect each country's science and technology policies.

In conclusion, we conducted impact analyses from multiple perspectives, including indicators related to substantiality² and index words profiling/clustering based on the national strategy.³ These findings may inform international collaborative long-term research that strategically leverages each research funding institution's strengths.

KEYWORDS




allergy, immunology, research impact analysis, research strategy, substantiality index

FUNDING INFORMATION

This research was supported by the Scientific Research Fund of the Ministry of Health, Labour and Welfare, Japan (201913009A, 21FE2001), JSPS KAKENHI (Grant Numbers: 16H06580 and 17K01173), and JST/RISTEX research funding program “Science of Science, Technology and Innovation Policy” (JPMJRX19B3).

ACKNOWLEDGEMENTS

We extend our special gratitude to Prof. Warwick Anderson (Former Secretary-General, International Human Frontier Science Program Organization) for his valuable suggestions regarding the manuscript. We also acknowledge Dr. Gavin Reddick at Interfolio UK for his support in the societal impact analysis.



(D)

No.	Area of research	AMED-PPAI	MRC-HIU	NIH-HAI	Others					
					2015-2019	2015	2016	2017	2018	2019
0	Hosts and microbiota	22%	6%	16%	12%	8%	9%	17%	7%	17%
1	Extracellular signals and immune responses	10%	26%	14%	22%	32%	23%	23%	21%	12%
2	Asthma/Atopic dermatitis and innate lymphoid cells	14%	8%	22%	6%	8%	7%	4%	3%	10%
3	Clinical management of immunological diseases	12%	4%	10%	9%	6%	6%	12%	8%	12%
4	Basic research for cancer immunotherapy	4%		8%	10%	7%	9%	10%	16%	8%
5	Infectious diseases including HIV	6%	12%		5%	4%	6%	4%	7%	5%
6	Lymphocyte subsets and functions		10%	10%	10%	15%	13%	6%	6%	11%
7	Macrophages, monocytes, dendritic cells and neutrophils	2%	2%	4%	6%	6%	9%	3%	5%	7%
8	Clinical management of allergic diseases	18%	18%		4%	4%	2%	5%	6%	2%
9	Omics and single cell analysis	10%	14%	6%	2%		1%		4%	6%
10	Clinical research for cancer immunotherapy				10%	7%	11%	9%	12%	10%
11	Neuroinflammation and central nervous system	2%		10%	4%	3%	4%	7%	5%	






FIGURE 1 Comparison of research impact of international funding agencies (FAs). Scholarly outputs from AMED-PPAI, MRC-HIU, and NIH-HAI were analyzed using FWCI (A) and international co-authorship ratio (B). UMAP with spectral clustering for dimension reduction of top 50 FWCI papers from three FAs (C, D) and relevance of each FA against twelve clusters (E). Cross-tabulation of MeSH headings' list of Actions of Strategy 2030 with list of top 50 papers from each FA (F) (box size: the percentage of papers with related MeSH; box color: standardized Pearson residuals). Objectives of engagement activities were listed for AMED-PPAI and UK comparator (G)

CONFLICT OF INTEREST

TF and AI are employees of the AMED. YO and KA are scientific advisors of AMED. MTa is the Program Officer, and HI is the Program Supervisor of the AMED-PPAI. TA (2015–2020) and YO (2018–2020) were employees of the AMED. SNi was the former Program Supervisor of the AMED-PPAI (2015–2018). The other details about competing interests are provided separately.

Takeya Adachi^{1,2,3,4} 
 Yasushi Ogawa^{5,6} 
 Tamami Fukushi⁷ 
 Kei Ito⁸
 Amane Koizumi⁹ 
 Masashi Shirabe¹⁰ 
 Masako Toriya¹¹ 
 Jun Hirako¹²
 Takenori Inomata^{1,13,14} 
 Katsunori Masaki^{1,15} 
 Ryohei Sasano¹²
 Sakura Sato^{1,16} 
 Keigo Kainuma¹⁷
 Masaki Futamura^{1,18} 
 Keiko Kan-o^{1,19} 
 Yosuke Kurashima^{1,20} 
 Saeko Nakajima^{1,21} 
 Masafumi Sakashita^{1,22}
 Hideaki Morita^{1,23,24} 
 Aikichi Iwamoto⁷ 
 Sankei Nishima²⁵
 Mayumi Tamari^{7,26} 
 Hajime Iizuka^{7,27}

¹ENGAGE-Task Force, Tokyo, Japan

²Keio Frontier Research & Education Collaborative Square (K-FRECS) at Tonomachi, Keio University, Kanagawa, Japan

³Department of Medical Regulatory Science, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan

⁴Department of Dermatology, Tachikawa Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, Japan

⁵Department of Advanced Medicine, Nagoya University, Nagoya, Japan

⁶Department of Dermatology, Nagoya University, Nagoya, Japan

⁷Japan Agency for Medical Research and Development (AMED), Tokyo, Japan

⁸Accenture Inc., Tokyo, Japan

⁹National Institutes of Natural Science (NINS), Tokyo, Japan

¹⁰Tokyo Institute of Technology, Tokyo, Japan

¹¹Global Research Institute, Keio University, Tokyo, Japan

¹²Graduate School of Informatics, Nagoya University, Nagoya, Japan

¹³Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan

¹⁴Department of Digital Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

¹⁵Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

¹⁶Department of Allergy, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagami-hara National Hospital, Kanagawa, Japan

¹⁷Institute for Clinical Research, National Hospital Organization Mie National Hospital, Mie, Japan

¹⁸Division of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

¹⁹Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

²⁰Department of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan

²¹Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan

²²Department of Otorhinolaryngology Head and Neck Surgery, University of Fukui, Fukui, Japan

²³Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan

²⁴Allergy Center, National Center for Child Health and Development, Tokyo, Japan

²⁵National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan

²⁶Division of Molecular Genetics, The Jikei University School of Medicine, Research Center for Medical Science, Tokyo, Japan

²⁷Research Institute of Psoriasis, Housui General Medical Clinic, Sapporo, Japan

Correspondence

Takeya Adachi, Department of Medical Regulatory Science, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, 602-8566 Kyoto, Japan.

Email: jpn4156@me.com

Takeya Adachi and Yasushi Ogawa authors contributed equally to
this work

ORCID

Takeya Adachi  <https://orcid.org/0000-0002-5289-5980>
 Yasushi Ogawa  <https://orcid.org/0000-0003-3553-9607>
 Tamami Fukushi  <https://orcid.org/0000-0003-4599-2413>
 Amane Koizumi  <https://orcid.org/0000-0003-1177-0185>
 Masashi Shirabe  <https://orcid.org/0000-0003-4569-6171>
 Masako Toriya  <https://orcid.org/0000-0002-8955-0353>
 Takenori Inomata  <https://orcid.org/0000-0003-3435-1055>
 Katsunori Masaki  <https://orcid.org/0000-0003-0909-9409>
 Sakura Sato  <https://orcid.org/0000-0003-3674-0759>
 Masaki Futamura  <https://orcid.org/0000-0002-7442-9649>
 Keiko Kan-o  <https://orcid.org/0000-0002-7736-588X>
 Yosuke Kurashima  <https://orcid.org/0000-0001-8588-4033>
 Saeko Nakajima  <https://orcid.org/0000-0003-0831-1447>
 Hideaki Morita  <https://orcid.org/0000-0003-0928-8322>
 Aikichi Iwamoto  <https://orcid.org/0000-0001-5868-7499>
 Mayumi Tamari  <https://orcid.org/0000-0002-5755-9177>

REFERENCES

1. Kamenetzky A, Hinrichs-Krapels S. How do organizations implement research impact assessment (RIA) principles and good

- practice? A narrative review and exploratory study of four international research funding and administrative organizations. *Health Res Policy Syst.* 2020;18:6.
2. Shirabe M, Koizumi A. Substantiality: a construct indicating research excellence to measure university research performance. *J Data Inf Sci.* 2021;6:1.
3. Adachi T, Kainuma K, Asano K, et al. Strategic outlook toward 2030: Japan's research for allergy and immunology - secondary publication. *Allergol Int.* 2020;69:561.
4. Cohan A, Feldman S, Beltagy I, Downey D, Weld DS, Assoc Computat L, SPECTER: document-level representation learning using citation-informed transformers. 58th Annual Meeting of the Association for Computational Linguistics (ACL 2020). 2020;2270.
5. Boulding H, Kamenetzky A, Ghiga I, et al. Mechanisms and pathways to impact in public health research: a preliminary analysis of research funded by the national institute for health research (NIHR). *BMC Med Res Methodol.* 2020;20:34.
6. The Swedish Foundation for International Cooperation in Research and Higher Education: Public Research and Innovation Funding Actors in China. https://www.stint.se/wp-content/uploads/2020/09/23087_STINT_rapport_Public_Research_and_Innovation_Funding_Actors_in_China_webb.pdf. Accessed January 13, 2022.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

DOI: 10.1111/all.15250

Gastrointestinal $\gamma\delta$ T cells reveal differentially expressed transcripts and enriched pathways during peanut oral immunotherapy

To the Editor,

Oral immunotherapy (OIT) has been successful in desensitizing patients to offending food allergens,¹ although the identification of tissue-resident T-cell subsets and cognate pathways leading to desensitization has been challenging. The $\gamma\delta$ T cells are a major T-cell subset of mucosal intraepithelial lymphocytes (IELs) and play a significant role in tissue homeostasis and repair.² In addition to aiding mucosal barrier function, $\gamma\delta$ T cells have also been recently discovered to be pivotal to cellular adaptations in response to nutrient sensing.³ In the broader context of atopy, $\gamma\delta$ T cells have been implicated both in IgE- and Th2-enhancing and IgE-suppressive effects.^{4,5} However, specifically with regard to peanut allergy, $\gamma\delta$ T cells were shown to be IgE-suppressive and thus protective in a study employing mouse models.⁶ In a recent study, peripheral $\gamma\delta$ Treg cells from

patients analyzed over 24 weeks of peanut OIT were shown to undergo dynamic changes in expression profiles, implicating pathways involved in immune homeostasis.⁷ To the best of our knowledge, the role of $\gamma\delta$ T cells in the intestinal mucosa of food allergic patients during immunotherapy has not been examined. To this end, we investigated whether $\gamma\delta$ T cells in the gastrointestinal (GI) tract exhibited changes during peanut OIT. We hypothesized that GI-resident $\gamma\delta$ T cells in peanut allergic patients would increase during the course of peanut OIT and might reveal transcripts and pathways relevant to the mechanisms of peanut desensitization.

Participants were recruited from a randomized, double-blind, placebo-controlled, phase II clinical trial of peanut OIT (POISED; NCT02103270).¹ Informed consent was obtained from all participants. Following dosage build-up over ~52 weeks, peanut-allergic